• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

野生型转甲状腺素蛋白淀粉样变性日本患者中期死亡率的预测

Prediction of Medium-Term Mortality in Japanese Patients With Wild-Type Transthyretin Amyloidosis.

作者信息

Ochi Yuri, Kubo Toru, Baba Yuichi, Nakashima Yasuteru, Ueda Motoko, Takahashi Asa, Miyagawa Kazuya, Noguchi Tatsuya, Hirota Takayoshi, Yamasaki Naohito, Kitaoka Hiroaki

机构信息

Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan.

出版信息

Circ Rep. 2020 Apr 29;2(6):314-321. doi: 10.1253/circrep.CR-20-0031.

DOI:10.1253/circrep.CR-20-0031
PMID:33693246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7925325/
Abstract

The prognostic factors in Japanese patients with wild-type transthyretin amyloidosis (ATTRwt) have not been elucidated. In this study we retrospectively analyzed the clinical characteristics and outcomes of 47 patients with ATTRwt (mean (±SD) age at diagnosis 80.3±4.6 years; 41 males). Fifteen patients died within 2 years of their diagnosis. Receiver operating characteristic and Kaplan-Meier analyses revealed that the best predictors of 2-year mortality were low serum albumin (≤3.75 g/dL), elevated high-sensitivity cardiac troponin T (hs-cTnT; >0.086 ng/mL), and reduced left ventricular ejection fraction (LVEF; <50%). According to the total number of these 3 risk factors, patients were stratified into 4 subgroups: low risk (no risk factors; n=15), intermediate-low risk (1 risk factor; n=15), intermediate-high risk (2 risk factors; n=7), and high risk (3 risk factors; n=10). The estimated 2-year survival rate of patients classified as low risk, intermediate-low risk, intermediate-high risk, and high risk was 93%, 80%, 83%, and 11%, respectively (P<0.001). Low serum albumin, elevated hs-cTnT, and reduced LVEF are associated with a worse prognosis in Japanese patients with ATTRwt. The combination of these factors may be useful for predicting medium-term mortality in patients with ATTRwt.

摘要

野生型转甲状腺素蛋白淀粉样变性(ATTRwt)日本患者的预后因素尚未阐明。在本研究中,我们回顾性分析了47例ATTRwt患者的临床特征和结局(诊断时平均(±标准差)年龄80.3±4.6岁;41例男性)。15例患者在诊断后2年内死亡。受试者工作特征曲线和Kaplan-Meier分析显示,2年死亡率的最佳预测因素是低血清白蛋白(≤3.75 g/dL)、高敏心肌肌钙蛋白T升高(hs-cTnT;>0.086 ng/mL)和左心室射血分数降低(LVEF;<50%)。根据这3个危险因素的总数,患者被分为4个亚组:低风险(无危险因素;n=15)、中低风险(1个危险因素;n=15)、中高风险(2个危险因素;n=7)和高风险(3个危险因素;n=10)。低风险、中低风险、中高风险和高风险患者的估计2年生存率分别为93%﹑80%﹑83%和11%(P<0.001)。低血清白蛋白、hs-cTnT升高和LVEF降低与ATTRwt日本患者的预后较差相关。这些因素相结合可能有助于预测ATTRwt患者的中期死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/a996b5482363/circrep-2-314-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/62aaa04b2a1f/circrep-2-314-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/47202daaa26a/circrep-2-314-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/96dc8ad202bf/circrep-2-314-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/35c726f8bc2a/circrep-2-314-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/a996b5482363/circrep-2-314-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/62aaa04b2a1f/circrep-2-314-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/47202daaa26a/circrep-2-314-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/96dc8ad202bf/circrep-2-314-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/35c726f8bc2a/circrep-2-314-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc31/7925325/a996b5482363/circrep-2-314-g005.jpg

相似文献

1
Prediction of Medium-Term Mortality in Japanese Patients With Wild-Type Transthyretin Amyloidosis.野生型转甲状腺素蛋白淀粉样变性日本患者中期死亡率的预测
Circ Rep. 2020 Apr 29;2(6):314-321. doi: 10.1253/circrep.CR-20-0031.
2
A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan.日本一种使用生物标志物的简单分期系统用于野生型转甲状腺素蛋白淀粉样心肌病。
ESC Heart Fail. 2022 Jun;9(3):1731-1739. doi: 10.1002/ehf2.13847. Epub 2022 Feb 22.
3
Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and Tc-pyrophosphate scintigraphy.采用高敏心肌肌钙蛋白 T 测定和 Tc-焦磷酸盐闪烁照相术对野生型转甲状腺素蛋白心脏淀粉样变性进行综合诊断。
J Cardiol. 2020 Jan;75(1):12-19. doi: 10.1016/j.jjcc.2019.05.011. Epub 2019 Jul 16.
4
Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.使用血清转甲状腺素蛋白作为野生型转甲状腺素蛋白相关性心脏淀粉样变性疾病的预后指标和结局预测因子。
Circ Heart Fail. 2018 Feb;11(2):e004000. doi: 10.1161/CIRCHEARTFAILURE.117.004000.
5
Prospective Multicenter Screening With High-Sensitivity Cardiac Troponin T for Wild-Type Transthyretin Cardiac Amyloidosis in Outpatient and Community-Based Settings.在门诊和社区环境中,采用高敏心肌肌钙蛋白T进行前瞻性多中心筛查野生型转甲状腺素蛋白心脏淀粉样变。
Circ J. 2024 Dec 25;89(1):24-30. doi: 10.1253/circj.CJ-24-0479. Epub 2024 Oct 4.
6
Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.经二尖瓣A波速度降低可预测老年左心室肥厚患者野生型转甲状腺素蛋白淀粉样变性的存在。
Heart Vessels. 2017 Jun;32(6):708-713. doi: 10.1007/s00380-016-0925-8. Epub 2016 Nov 23.
7
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.野生型转甲状腺素蛋白心脏淀粉样变性的自然病史和使用新型分期系统进行风险分层。
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. doi: 10.1016/j.jacc.2016.06.033.
8
Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.通气效率斜率作为野生型转甲状腺素蛋白心脏淀粉样变患者死亡率增加的标志物的应用。
Am J Cardiol. 2019 Jul 1;124(1):122-130. doi: 10.1016/j.amjcard.2019.03.035. Epub 2019 Apr 9.
9
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).野生型转甲状腺素蛋白淀粉样变性的性别差异:来自转甲状腺素蛋白淀粉样变性结局调查(THAOS)的分析。
Cardiol Ther. 2022 Sep;11(3):393-405. doi: 10.1007/s40119-022-00265-7. Epub 2022 May 18.
10
Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.转甲状腺素相关与轻链心脏淀粉样变性的左心室结构和功能。
Circulation. 2014 May 6;129(18):1840-9. doi: 10.1161/CIRCULATIONAHA.113.006242. Epub 2014 Feb 21.

引用本文的文献

1
Incidental Finding of Transthyretin Cardiac Amyloidosis During Coronary Artery Bypass Grafting.冠状动脉旁路移植术中甲状腺素运载蛋白型心脏淀粉样变的偶然发现
Cureus. 2024 May 1;16(5):e59466. doi: 10.7759/cureus.59466. eCollection 2024 May.
2
Usefulness of quantitative Tc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis.定量 Tc-焦磷酸盐 SPECT/CT 预测野生型转甲状腺素蛋白心脏淀粉样变患者预后的价值。
Jpn J Radiol. 2022 May;40(5):508-517. doi: 10.1007/s11604-021-01221-6. Epub 2022 Jan 1.
3
Tenosynovial and Cardiac Transthyretin Amyloidosis in Japanese Patients Undergoing Carpal Tunnel Release.

本文引用的文献

1
A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.关于转甲状腺素蛋白心脏淀粉样变患者塔法米迪司给药的声明。
Circ J. 2019 Dec 25;84(1):15-17. doi: 10.1253/circj.CJ-19-0811. Epub 2019 Nov 16.
2
Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and Tc-pyrophosphate scintigraphy.采用高敏心肌肌钙蛋白 T 测定和 Tc-焦磷酸盐闪烁照相术对野生型转甲状腺素蛋白心脏淀粉样变性进行综合诊断。
J Cardiol. 2020 Jan;75(1):12-19. doi: 10.1016/j.jjcc.2019.05.011. Epub 2019 Jul 16.
3
Geriatric nutritional risk index predicts all-cause deaths in heart failure with preserved ejection fraction.
接受腕管松解术的日本患者的腱鞘和心脏转甲状腺素蛋白淀粉样变性
Circ Rep. 2021 May 27;3(6):338-344. doi: 10.1253/circrep.CR-21-0046.
老年营养风险指数可预测射血分数保留的心力衰竭患者的全因死亡。
ESC Heart Fail. 2019 Apr;6(2):396-405. doi: 10.1002/ehf2.12405. Epub 2019 Feb 1.
4
Low serum albumin: A significant predictor of reduced survival in patients with chronic heart failure.低血清白蛋白:慢性心力衰竭患者生存预后不良的重要预测指标。
Clin Cardiol. 2019 Mar;42(3):365-372. doi: 10.1002/clc.23153. Epub 2019 Feb 7.
5
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
6
Native T1 and Extracellular Volume in Transthyretin Amyloidosis.转甲状腺素蛋白淀粉样变性中的固有 T1 值和细胞外容积。
JACC Cardiovasc Imaging. 2019 May;12(5):810-819. doi: 10.1016/j.jcmg.2018.02.006. Epub 2018 Mar 14.
7
Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.使用血清转甲状腺素蛋白作为野生型转甲状腺素蛋白相关性心脏淀粉样变性疾病的预后指标和结局预测因子。
Circ Heart Fail. 2018 Feb;11(2):e004000. doi: 10.1161/CIRCHEARTFAILURE.117.004000.
8
Impact of nutritional indices on mortality in patients with heart failure.营养指标对心力衰竭患者死亡率的影响。
Open Heart. 2018 Jan 9;5(1):e000730. doi: 10.1136/openhrt-2017-000730. eCollection 2018.
9
First nationwide survey on systemic wild-type ATTR amyloidosis in Japan.日本全国范围内系统性野生型 ATTR 淀粉样变的首次调查。
Amyloid. 2018 Mar;25(1):8-10. doi: 10.1080/13506129.2017.1409706. Epub 2017 Nov 28.
10
A new staging system for cardiac transthyretin amyloidosis.心脏转甲状腺素蛋白淀粉样变性的新分期系统。
Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.